Catalyst
Slingshot members are tracking this event:
Gilead Sciences (GILD) plans to fully enroll Phase 3 STELLAR 4 trial for nonalcoholic steatohepatitis (NASH) evaluating selonsertib in treating F4 cirrhosis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 23, 2018
Occurred Source:
https://clinicaltrials.gov/ct2/history/NCT03053063?V_20=View#StudyPageTop
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nash Cirrhosis, Selonsertib, Phase 3, Stellar Trial
